Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L-carnitine-containing peritoneal dialysis solution vs standard glucose solution in type 2 diabetes CAPD patients with ESRD
2006-005300-13Phase 2Terminated
- Sponsor
- Iperboreal Pharma
- Start
- May 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of levocarnitine in end-stage kidney disease (ESKD), type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) (2 arms), sponsored by Iperboreal Pharma. Primary endpoint: Insulin sensitivity. Started May 2007; status: terminated.
02
Drugs
levocarnitine
03
Conditions
end-stage kidney disease (ESKD)type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2006-005300-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005300-13.